SETD3 and cancer: Indeed, a line of clinical evidence further supports the notion that elevated SETD3 expression is closely correlated with high levels of cell proliferation and advanced-grade malignancy, suggesting that SETD3 protein levels might be considered a potential biomarker for predicting cancer progression and patient prognosis (19).